SK115097A3 - Hepatitis b vaccine, method of producing and its use - Google Patents

Hepatitis b vaccine, method of producing and its use Download PDF

Info

Publication number: SK115097A3
Authority: SK; Slovakia
Prior art keywords: hepatitis; vaccine; antigen; hbsag; vaccine according
Prior art date: 1995-02-25

Application number

SK1150-97A

Other languages

English (en)

Slovak (sk)

Inventor

Pierre Hauser

Nathalie Marie-Josephe Garcon

Pierre Desmons

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-25

Filing date

1996-02-15

Publication date

1998-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK115097(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-02-15 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

1998-02-04 Publication of SK115097A3 publication Critical patent/SK115097A3/sk

Links

238000000034 method Methods 0.000 title claims description 10
229940124736 hepatitis-B vaccine Drugs 0.000 title description 5
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 title description 3
229960005486 vaccine Drugs 0.000 claims abstract description 51
239000000427 antigen Substances 0.000 claims abstract description 39
102000036639 antigens Human genes 0.000 claims abstract description 39
108091007433 antigens Proteins 0.000 claims abstract description 39
208000002672 hepatitis B Diseases 0.000 claims abstract description 25
239000000203 mixture Substances 0.000 claims abstract description 16
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract description 14
229940035032 monophosphoryl lipid a Drugs 0.000 claims abstract description 12
208000006454 hepatitis Diseases 0.000 claims description 10
231100000283 hepatitis Toxicity 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 8
230000003472 neutralizing effect Effects 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 6
201000005702 Pertussis Diseases 0.000 claims description 5
206010043376 Tetanus Diseases 0.000 claims description 5
206010013023 diphtheria Diseases 0.000 claims description 5
230000001939 inductive effect Effects 0.000 claims description 5
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
208000005252 hepatitis A Diseases 0.000 claims description 4
102100031673 Corneodesmosin Human genes 0.000 claims description 3
101710139375 Corneodesmosin Proteins 0.000 claims description 3
101710137302 Surface antigen S Proteins 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
229940029583 inactivated polio vaccine Drugs 0.000 claims description 3
238000011321 prophylaxis Methods 0.000 claims description 3
241000606790 Haemophilus Species 0.000 claims description 2
241000282412 Homo Species 0.000 claims description 2
201000009906 Meningitis Diseases 0.000 claims description 2
208000000474 Poliomyelitis Diseases 0.000 claims description 2
239000011246 composite particle Substances 0.000 claims description 2
230000004224 protection Effects 0.000 claims description 2
108010066124 Protein S Proteins 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 claims 1
108700017737 hepatitis B virus L Proteins 0.000 claims 1
108010026228 mRNA guanylyltransferase Proteins 0.000 claims 1
229940021747 therapeutic vaccine Drugs 0.000 claims 1
238000009472 formulation Methods 0.000 abstract description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000002245 particle Substances 0.000 description 7
230000004044 response Effects 0.000 description 6
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 6
229960004906 thiomersal Drugs 0.000 description 6
241000700721 Hepatitis B virus Species 0.000 description 5
229960002520 hepatitis vaccine Drugs 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
229940124884 Engerix-B Drugs 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000000243 solution Substances 0.000 description 4
206010019799 Hepatitis viral Diseases 0.000 description 3
241000700605 Viruses Species 0.000 description 3
229940001442 combination vaccine Drugs 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
201000001862 viral hepatitis Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
229910017119 AlPO Inorganic materials 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
108010084884 GDP-mannose transporter Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229940124914 Havrix Drugs 0.000 description 1
206010073069 Hepatic cancer Diseases 0.000 description 1
229940124915 Infanrix Drugs 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007689 endotoxicity Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
108010091718 peptide L Proteins 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1150-97A 1995-02-25 1996-02-15 Hepatitis b vaccine, method of producing and its use SK115097A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9503863.4A GB9503863D0 (en)	1995-02-25	1995-02-25	Vaccine compositions
PCT/EP1996/000681 WO1996026741A1 (en)	1995-02-25	1996-02-15	Hepatitis b vaccine

Publications (1)

Publication Number	Publication Date
SK115097A3 true SK115097A3 (en)	1998-02-04

Family

ID=10770292

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1150-97A SK115097A3 (en)	1995-02-25	1996-02-15	Hepatitis b vaccine, method of producing and its use

Country Status (35)

Country	Link
US (1)	US5972346A (de)
EP (1)	EP0810877B1 (de)
JP (1)	JP3881015B2 (de)
KR (1)	KR100365373B1 (de)
CN (1)	CN1101225C (de)
AP (1)	AP766A (de)
AR (1)	AR002279A1 (de)
AT (1)	ATE209045T1 (de)
AU (1)	AU695921B2 (de)
BG (1)	BG101851A (de)
BR (1)	BR9607458A (de)
CA (1)	CA2212552C (de)
CZ (1)	CZ288417B6 (de)
DE (1)	DE69617211T2 (de)
DK (1)	DK0810877T3 (de)
EA (1)	EA199700126A1 (de)
ES (1)	ES2166879T3 (de)
FI (1)	FI118118B (de)
GB (1)	GB9503863D0 (de)
HU (1)	HU224832B1 (de)
IL (1)	IL117249A (de)
MA (1)	MA23814A1 (de)
MX (1)	MX9706450A (de)
MY (1)	MY113428A (de)
NO (1)	NO319394B1 (de)
NZ (1)	NZ302674A (de)
OA (1)	OA10612A (de)
PL (1)	PL182679B1 (de)
PT (1)	PT810877E (de)
SA (1)	SA96160633B1 (de)
SK (1)	SK115097A3 (de)
TR (1)	TR199700849T1 (de)
TW (1)	TW467745B (de)
WO (1)	WO1996026741A1 (de)
ZA (1)	ZA961460B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6620414B2 (en) *	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr)	1993-10-22	1996-01-12	Pasteur Institut	Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) *	1995-02-25	2002-12-03	Smithkline Beecham Biologicals S.A.	Hepatitis B vaccine
US20010014331A1 (en) *	1996-11-07	2001-08-16	Smithkline Beecham Biologicals S.A.	Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
US20030049268A1 (en)	1998-05-01	2003-03-13	Smithkline Beecham Biologicals S.A.	Novel composition
GB9809507D0 (en) *	1998-05-01	1998-07-01	Smithkline Beecham Biolog	Novel composition
SI1077722T1 (sl)	1998-05-22	2007-02-28	Ottawa Health Research Inst	Metode in produkti za induciranje sluznicne imunosti
US6306404B1 (en)	1998-07-14	2001-10-23	American Cyanamid Company	Adjuvant and vaccine compositions containing monophosphoryl lipid A
KR100629028B1 (ko)	1998-10-16	2006-09-26	글락소스미스클라인 바이오로지칼즈 에스.에이.	애쥬번트 시스템 및 백신
CU22871A1 (es) *	1998-12-02	2003-10-21	Ct Ingenieria Genetica Biotech	Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
AU2212100A (en) *	1998-12-23	2000-07-12	Merck & Co., Inc.	Improved recombinant hepatitis b surface antigen
PT1187629E (pt)	1999-04-19	2005-02-28	Glaxosmithkline Biolog Sa	Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6635261B2 (en)	1999-07-13	2003-10-21	Wyeth Holdings Corporation	Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) *	2002-01-24	2005-02-23	Ct Ingenieria Genetica Biotech	Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
NZ560930A (en) *	2005-02-16	2011-06-30	Novartis Vaccines & Diagnostic	Hepatitis B virus vaccine comprising a hepatitis B virus surface antigen, aluminium phosphate, 3-O-deacylated monophosphoryl lipid A and a triethylammonium ion
DK1909830T3 (da) *	2005-08-02	2011-12-19	Novartis Vaccines & Diagnostic	Formindskelse af interferens mellem olieholdige adjuvanser og antigener indeholdende overfladeaktivt middel
CA2628152C (en)	2005-11-04	2016-02-02	Novartis Vaccines And Diagnostics S.R.L.	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568211A (en)	2005-11-04	2011-11-25	Novartis Vaccines & Diagnostic	Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ594482A (en)	2005-11-04	2012-11-30	Novartis Vaccines & Diagnostic	Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CN102755645A (zh)	2005-11-04	2012-10-31	诺华疫苗和诊断有限公司	佐剂配制的包含细胞因子诱导剂的流感疫苗
CN100415294C (zh) *	2005-12-23	2008-09-03	中国农业大学	一种治疗和/或预防乙肝的药物
PL2478916T3 (pl)	2006-01-27	2020-11-16	Seqirus UK Limited	Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
ES2536426T3 (es)	2006-03-23	2015-05-25	Novartis Ag	Compuestos de imidazoquinoxalina como inmunomoduladores
CN101448523A (zh)	2006-03-24	2009-06-03	诺华疫苗和诊断有限两合公司	无需冷藏储存流感疫苗
EP1862176A1 (de) *	2006-05-31	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) *	2006-06-01	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Ein Verfahren zur Herstellung einer Impfzusammensetzung
PT2054431E (pt)	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
EP4585610A3 (de)	2006-09-11	2025-09-24	Seqirus UK Limited	Herstellung von influenzavirus-impfstoffen ohne verwendung von eiern
PT2121011E (pt)	2006-12-06	2014-07-31	Novartis Ag	Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
KR20100045437A (ko)	2007-06-27	2010-05-03	노파르티스 아게	첨가물이 적은 인플루엔자 백신
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en)	2007-12-24	2014-07-24	Novartis Ag	Assays for adsorbed influenza vaccines
CA2768186A1 (en)	2009-07-15	2011-01-20	Novartis Ag	Rsv f protein compositions and methods for making same
WO2012103361A1 (en)	2011-01-26	2012-08-02	Novartis Ag	Rsv immunization regimen
US9452212B2 (en)	2011-04-14	2016-09-27	Dynavax Technologies Corporation	Methods and compositions for eliciting an immune response against hepatitis B virus
CA2835644C (en)	2011-05-13	2021-06-15	Novartis Ag	Pre-fusion rsv f antigens
US11013795B2 (en)	2015-06-26	2021-05-25	Seqirus UK Limited	Antigenically matched influenza vaccines
WO2020099927A1 (en)	2018-11-13	2020-05-22	Variation Biotechnologies Inc.	Immunogenic compositions for treatment of hepatitis b

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
EP0414374B1 (de) *	1989-07-25	1997-10-08	Smithkline Biologicals S.A.	Antigene sowie Verfahren zu deren Herstellung
DK0637223T3 (da) *	1991-05-29	1999-04-26	Origin Medsystems Inc	Tilbageholdelsesanordning til endoskopisk kirurgi
MA22842A1 (fr) *	1992-03-27	1993-10-01	Smithkline Beecham Biolog	Procede de preparation de compositions de vaccin.
SG48365A1 (en) *	1992-05-23	1998-04-17	Smithkline Beecham Biolog	Combined vaccines comprising hepatitis b surface antigen and other antigens
US5776468A (en) *	1993-03-23	1998-07-07	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9311536D0 (en) *	1993-06-04	1993-07-21	Unilever Plc	Hot soluble low density extractable food product

1995
- 1995-02-25 GB GBGB9503863.4A patent/GB9503863D0/en active Pending
1996
- 1996-02-14 MY MYPI96000567A patent/MY113428A/en unknown
- 1996-02-15 PT PT96904814T patent/PT810877E/pt unknown
- 1996-02-15 WO PCT/EP1996/000681 patent/WO1996026741A1/en not_active Ceased
- 1996-02-15 BR BR9607458A patent/BR9607458A/pt not_active IP Right Cessation
- 1996-02-15 ES ES96904814T patent/ES2166879T3/es not_active Expired - Lifetime
- 1996-02-15 AT AT96904814T patent/ATE209045T1/de active
- 1996-02-15 KR KR1019970705880A patent/KR100365373B1/ko not_active Expired - Fee Related
- 1996-02-15 TR TR97/00849T patent/TR199700849T1/xx unknown
- 1996-02-15 HU HU9801242A patent/HU224832B1/hu not_active IP Right Cessation
- 1996-02-15 SK SK1150-97A patent/SK115097A3/sk unknown
- 1996-02-15 EP EP96904814A patent/EP0810877B1/de not_active Expired - Lifetime
- 1996-02-15 DE DE69617211T patent/DE69617211T2/de not_active Expired - Lifetime
- 1996-02-15 NZ NZ302674A patent/NZ302674A/xx not_active IP Right Cessation
- 1996-02-15 US US08/894,643 patent/US5972346A/en not_active Expired - Lifetime
- 1996-02-15 CN CN96192146A patent/CN1101225C/zh not_active Expired - Fee Related
- 1996-02-15 CZ CZ19972674A patent/CZ288417B6/cs not_active IP Right Cessation
- 1996-02-15 DK DK96904814T patent/DK0810877T3/da active
- 1996-02-15 JP JP52598896A patent/JP3881015B2/ja not_active Expired - Fee Related
- 1996-02-15 AU AU48780/96A patent/AU695921B2/en not_active Ceased
- 1996-02-15 PL PL96321966A patent/PL182679B1/pl unknown
- 1996-02-15 AP APAP/P/1997/001060A patent/AP766A/en active
- 1996-02-15 EA EA199700126A patent/EA199700126A1/ru unknown
- 1996-02-15 CA CA002212552A patent/CA2212552C/en not_active Expired - Fee Related
- 1996-02-22 AR ARP960101469A patent/AR002279A1/es active IP Right Grant
- 1996-02-23 MA MA24171A patent/MA23814A1/fr unknown
- 1996-02-23 ZA ZA961460A patent/ZA961460B/xx unknown
- 1996-02-23 IL IL11724996A patent/IL117249A/xx not_active IP Right Cessation
- 1996-02-26 TW TW085102154A patent/TW467745B/zh not_active IP Right Cessation
- 1996-03-02 SA SA96160633A patent/SA96160633B1/ar unknown
1997
- 1997-08-02 OA OA70066A patent/OA10612A/en unknown
- 1997-08-22 FI FI973457A patent/FI118118B/fi not_active IP Right Cessation
- 1997-08-22 NO NO19973873A patent/NO319394B1/no not_active IP Right Cessation
- 1997-08-22 MX MX9706450A patent/MX9706450A/es unknown
- 1997-08-25 BG BG101851A patent/BG101851A/xx unknown

Also Published As

Publication number	Publication date
HK1004117A1 (en)	1998-11-20
BR9607458A (pt)	1998-06-30
AU4878096A (en)	1996-09-18
CA2212552C (en)	2006-07-11
FI973457L (fi)	1997-08-22
AP9701060A0 (en)	1997-10-31
CA2212552A1 (en)	1996-09-06
JPH11501018A (ja)	1999-01-26
AU695921B2 (en)	1998-08-27
MX9706450A (es)	1998-07-31
SA96160633B1 (ar)	2005-10-15
DK0810877T3 (da)	2002-02-25
NO973873L (no)	1997-08-22
IL117249A (en)	2000-11-21
AR002279A1 (es)	1998-03-11
EP0810877B1 (de)	2001-11-21
NO319394B1 (no)	2005-08-08
CN1101225C (zh)	2003-02-12
JP3881015B2 (ja)	2007-02-14
EP0810877A1 (de)	1997-12-10
HU224832B1 (en)	2006-03-28
CN1176604A (zh)	1998-03-18
EA199700126A1 (ru)	1998-02-26
PL182679B1 (pl)	2002-02-28
TW467745B (en)	2001-12-11
FI973457A0 (fi)	1997-08-22
MY113428A (en)	2002-02-28
CZ288417B6 (en)	2001-06-13
IL117249A0 (en)	1996-06-18
WO1996026741A1 (en)	1996-09-06
AP766A (en)	1999-09-17
DE69617211D1 (en)	2002-01-03
FI118118B (fi)	2007-07-13
PT810877E (pt)	2002-04-29
HUP9801242A3 (en)	2000-08-28
ZA961460B (en)	1996-08-29
HUP9801242A1 (hu)	1998-08-28
GB9503863D0 (en)	1995-04-19
US5972346A (en)	1999-10-26
KR100365373B1 (ko)	2003-07-07
CZ267497A3 (cs)	1998-02-18
ATE209045T1 (de)	2001-12-15
MA23814A1 (fr)	1996-10-01
BG101851A (en)	1998-04-30
ES2166879T3 (es)	2002-05-01
NO973873D0 (no)	1997-08-22
DE69617211T2 (de)	2002-07-25
TR199700849T1 (xx)	1998-01-21
OA10612A (en)	2002-08-29
PL321966A1 (en)	1998-01-05
KR19980702480A (ko)	1998-07-15
NZ302674A (en)	1999-01-28

Publication	Publication Date	Title
AP766A (en)	1999-09-17	A vaccine based on hepatitis B antigen.
CA2132833C (en)	2007-03-06	Hepatitis vaccines containing 3-o-deacylated monophosphoryl lipid a
US6620414B2 (en)	2003-09-16	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
US6488934B1 (en)	2002-12-03	Hepatitis B vaccine
KR20010043224A (ko)	2001-05-25	백신 조성물
HK1004117B (en)	2002-09-20	Hepatitis b vaccine
HK1003218B (en)	1998-10-16	Hepatitis vaccins containing 3-0 deacylated monophosphoryl lipid a